|
|
|
|
|
|
Sponsors and Collaborators: |
Ireland Cancer Center National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00006465 |
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have advanced solid tumors.
Condition | Intervention | Phase |
Unspecified Adult Solid Tumor, Protocol Specific |
Drug: capecitabine Drug: irinotecan hydrochloride Drug: oxaliplatin |
Phase I |
MedlinePlus related topics: | Cancer |
ChemIDplus related topics: | Irinotecan Irinotecan hydrochloride Capecitabine Oxaliplatin |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | Phase I Study of Oxaliplatin (NSC# 266046), Irinotecan, and Capecitabine in Patients With Solid Tumors |
Study Start Date: | December 2000 |
OBJECTIVES:
OUTLINE: This is a dose-escalation study of irinotecan and capecitabine.
Patients receive oxaliplatin IV over 2 hours followed 1 hour later by irinotecan IV over 30 minutes once weekly for 4 weeks. Patients also receive oral capecitabine twice daily on days 1-5 weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of irinotecan and capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
PROJECTED ACCRUAL: Approximately 9-15 patients will be accrued for this study within 9-15 months.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
United States, Ohio | |||||
Ireland Cancer Center | |||||
Cleveland, Ohio, United States, 44106-5065 | |||||
United States, Pennsylvania | |||||
University of Pittsburgh Cancer Institute | |||||
Pittsburgh, Pennsylvania, United States, 15213-1863 |
Ireland Cancer Center |
National Cancer Institute (NCI) |
Study Chair: | Scot C. Remick, MD | Case Comprehensive Cancer Center |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000068278, CWRU-5Y99, NCI-370 |
First Received: | November 6, 2000 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00006465 |
Health Authority: | United States: Federal Government |
|
|
|
|